1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Mendus AB (publ)

Mendus AB (publ)

IMMU.ST
Mendus AB (publ)SE flagStockholm Stock Exchange
6.79
SEK
+0.68
- -
344.62MMarket Cap
Mendus AB (publ)
IMMU.ST
(Stockholm Stock Exchange)

Recent

price

6.79

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-2.58
-3.01
-4.79
-8.27
-18.33
-30.49
-37.35
-57.01
-35.08
-11.91
-21.57
-13.36
-13.92
-4.39
-2.64
-2.17
-1.89
Basic EPS, GAAP
- -
-2.26
-5.53
-8.65
-10.86
-34.34
-34.21
-32.96
-37.52
-14.55
-13.91
-13.96
-12.2
-7.12
-1.68
-1.57
-1.59
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-3.83
-6.84
-13.4
-21.91
-38.67
-59.7
-96.38
-162.68
-77.5
-65.79
-83.5
-47.78
-61.79
-29.59
-16.59
-17.37
-16.93
Book Value per Share
6.3
2.91
2.58
29.53
113.62
55.33
118.34
134.52
-9.33
-1.41
31.1
12.45
-1.81
7.45
2.32
1.01
0.6
Tangible Book Value per Share
1
1
1
1
1
1
1
1
3
4
4
10
10
23
49
52
55
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
-86,107.32
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
2
5
6
6
6
6
Depreciation Expense
-2
-3
-4
-7
-16
-36
-44
-80
-98
-48
-89
-133
-139
-102
-128
-113
-104
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-84,817.82
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
6
3
5
25
101
65
123
85
-1
22
144
158
-12
159
103
46
28
Working Capital
1
1
1
1
1
1
1
1
2
32
19
37
47
22
20
16
15
LT Debt
7
4
4
25
100
65
139
190
-26
-6
661
657
514
705
645
585
565
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
4
3
3
LT Borrowings
- -
1
- -
LT Finance Leases
- -
15
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
52
61
61
Market Capitalization
338
290
246

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
61
73
81
Cash, Cash Equivalents & STI
38
65
74
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
25
27
53
Payables & Accruals
- -
- -
- -
ST Debt
4
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1,178.86%
-0.62%
-9.31%
Free Cash Flow
21.02%
22.94%
0.41%
Net Income, GAAP
20.5%
8.26%
-11.79%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.83
-0.76
-0.46
-0.63
-2.64
2025
-0.61
-0.45
-0.37
-0.74
-2.17
2026
-0.34
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Defence Therapeutics Inc. (DTC.CN)
Ardelyx, Inc. (ARDX)
Gelesis Holdings, Inc. (GLSHQ)
EvoNext Holdings S.A. (ELVAF)
BioInvent International AB (publ) (0H22.L)
Vincerx Pharma, Inc. (VINCU)
Business
Mendus AB (publ) (Nasdaq Stockholm: IMMU), a clinical-stage biopharmaceutical company, develops off-the-shelf, cell-based immunotherapies leveraging allogeneic dendritic cell biology to treat tumor recurrence and improve survival outcomes in cancer patients while preserving quality of life; its lead candidate vididencel (DCP-001) advances in the Phase II ADVANCE-II trial as maintenance therapy for acute myeloid leukemia (AML), the Phase II CADENCE trial combining vididencel with oral azacitidine in AML supported by the Australasian Leukaemia and Lymphoma Group, and the Phase I ALISON trial in ovarian cancer; additional pipeline assets include ilixadencel in Phase I/II for soft tissue sarcomas and a preclinical NK cell program targeting natural killer cell-based therapies. The company maintains operations in Sweden, with its primary headquarters at Västra Trädgårdsgatan 15 in Stockholm, and the Netherlands, including its main R&D center in Leiden as a wholly owned subsidiary Mendus BV; founded in 2002 as Immunicum AB (publ), it rebranded to Mendus AB (publ) in June 2022. Recent developments encompass supportive feedback from the European Medicines Agency and U.S. Food and Drug Administration on Phase 3 trial design for vididencel in AML during Q1 2025, alongside first patient enrollment in the AMLM22-CADENCE trial in February 2025; Mendus progresses large-scale GMP production of vididencel targeted for the second half of 2025 through its manufacturing alliance with NorthX Biologics, executes a directed share issue of approximately SEK 52.5 million in November 2025 to fund clinical milestones, and updates its clinical development strategy based on positive survival data from ADVANCE-II presented at the American Society of Hematology 2024 meeting.